<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The diagnostic and therapeutic approach to the problem of mural <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> after <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> is uncertain </plain></SENT>
<SENT sid="1" pm="."><plain>It is clear that the main therapeutic goal is the prevention of embolic <z:hpo ids='HP_0001297'>strokes</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Although it is known that the incidence of <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> is greatest after anterior wall infarctions, there is uncertainty concerning (1) the probability of a <z:e sem="disease" ids="C0333205,C1260883" disease_type="Disease or Syndrome" abbrv="">mural thrombus</z:e>; (2) the sensitivity and specificity of echocardiography in making the diagnosis; (3) the probability that a <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> will embolize and result in a <z:hpo ids='HP_0001297'>cerebrovascular accident</z:hpo> (<z:chebi fb="4" ids="46274">CVA</z:chebi>); (4) the efficacy of <z:chebi fb="8" ids="10033">warfarin</z:chebi> in preventing embolization; and (5) the probability of <z:mp ids='MP_0001914'>bleeding</z:mp> with and without <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>To study this problem in patients who have had an anterior wall <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, a model was created in which reasonable estimates for the unknown parameters were determined from published medical studies </plain></SENT>
<SENT sid="4" pm="."><plain>The model was designed to consider patients if they were or were not treated during the initial hospitalization with <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The probability of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was estimated at 0.30, sensitivity and specificity of echocardiography at 0.85 and 0.85, probability that a <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> will embolize at 0.15, efficacy of anticoagulation of 0.75, probability of <z:mp ids='MP_0001914'>bleeding</z:mp> with <z:chebi fb="8" ids="10033">warfarin</z:chebi> at 0.03 and probability of <z:mp ids='MP_0001914'>bleeding</z:mp> without <z:chebi fb="8" ids="10033">warfarin</z:chebi> at 0.005 </plain></SENT>
<SENT sid="6" pm="."><plain>Probabilities of a <z:chebi fb="4" ids="46274">CVA</z:chebi> and of <z:mp ids='MP_0001914'>bleeding</z:mp> with and without <z:chebi fb="8" ids="10033">warfarin</z:chebi> were determined if <z:hpo ids='HP_0000001'>all</z:hpo> patients were anticoagulated, if patients with positive echocardiographic results were treated, if patients with negative echocardiographic results were treated and if echocardiographically guided therapy was instituted in which patients with positive echocardiographic results are treated and patients with negative results are not treated.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>